GERON CORP Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
GERON CORP (GERN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $259.00 thousand as of 2018-06-30, per its 10-Q filed 2018-07-31.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2018-07-31
- 2018-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $259.00K.
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $338.00K.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $211.00K.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $80.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2018-06-30 | $259.00K 10-Q · filed 2018-07-31 |
| 2018-03-31 | $338.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $211.00K 10-Q · filed 2018-07-31 |
| 2017-09-30 | $80.00K 10-Q · filed 2017-11-01 |
| 2017-06-30 | $98.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $93.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $107.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $53.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $25.00K 10-Q · filed 2016-08-03 |
| 2016-03-31 | $47.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $263.00K 10-K · filed 2017-03-01 |
| 2015-09-30 | $81.00K 10-Q · filed 2015-11-05 |
| 2014-12-31 | $100.00K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |